- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06266832
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma: A Prospective, Single-arm Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: sheng dai, MD&PhD
- Phone Number: 13575472669
- Email: daimd@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
- Recruiting
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
-
Contact:
- Xiujun Cai
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients who are willing to receive neoadjuvant therapy.
- ≧18 years old.
- Diagnosed by digital rectal examination, colonoscopy, and high-resolution MRI of the pelvis, the tumor is less than or equal to 5 cm from the anus.
- Histologically diagnosed as rectal adenocarcinoma.
- MMR protein detection or MSI gene detection of rectal cancer specimens confirmed pMMR or MSS before treatment .
- The clinical staging by pelvic contrast-enhanced CT and pelvic high-resolution MRI were stage I, II and III.
- The patient has good compliance and can come to the hospital for re-examination as required.
- ECOG Scale of Performance Status score 0-1 point.
- Have not received anti-tumor and immunotherapy before enrollment.
Laboratory inspections must meet the following standards:
- White blood cell count>3.5×109/L, absolute value of neutrophils>1.8×109/L, platelet count ≥75×109/L, hemoglobin ≥100g/L;
- INR≤1.5, and APTT≤1.5 times the upper limit of normal or partial prothrombin time (PT) ≤1.5 times the upper limit of normal;
- Total bilirubin ≤ 1.25 times the upper limit of normal; ALT and AST < 5 times the upper limit of normal;
- 24h creatinine clearance >50mL/min or serum creatinine <1.5 times the upper limit of normal.
- Voluntarily participate in this study and sign the informed consent.
Exclusion Criteria:
- History of other malignant diseases other than rectal cancer in the past 5 years.
- Patients with metastases from other sites (stage IV patients).
- Patients with intestinal obstruction, intestinal perforation, intestinal bleeding, etc. requiring emergency surgery.
- Known allergic to oxaliplatin, capecitabine, Adebrelimab and other drugs.
- Pathologically suggested signet ring cell carcinoma and mucinous adenocarcinoma.
- dMMR or MSI-H patients.
- The patient is accompanied by any unstable systemic disease, including but not limited to: severe infection, uncontrolled diabetes, hypertension uncontrolled by medication, unstable angina, cerebrovascular accident or transient cerebral ischemia, myocardial Infarction, congestive heart failure, severe cardiac arrhythmia requiring medication, hepatic, renal or metabolic disease; disease affecting the patient's life.
- The disease (such as mental illness, etc.) or condition (such as alcoholism or drug abuse, etc.) associated with the patient will increase the risk of the patient receiving the trial drug treatment or affect the patient's compliance with the trial requirements, or may confuse the research results.
- Active autoimmune disease that may worsen while receiving immunostimulants.
- Known history of positive HIV test or known acquired immunodeficiency syndrome.
Patients who are using immunosuppressive agents, except for the following conditions:
- Intranasal, inhaled, topical steroids, or topical steroid injections (eg, intra-articular injections);
- Physiological doses of systemic corticosteroids ≤10 mg/day prednisone or equivalent; 3) Steroids used to prevent allergic reactions (eg, before CT scan).
- Received any other experimental drug treatment or participated in another interventional clinical trial within 30 days before screening.
- Women who are pregnant or breastfeeding or who plan to become pregnant or breastfeeding during the study period; men or women who are unwilling to take effective contraceptive measures.
- Vulnerable groups, including mentally ill, cognitively impaired, critically ill patients, minors, etc.
- Other conditions that the investigator judges that the patient is not suitable to participate in the clinical study, etc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Total Neoadjuvant Therapy with Short-course Radiation followed by Adebrelimab plus CAPEOX
The enrolled patients with MSS-type advanced ultra low rectal adenocarcinoma will receive a combined regimen of neoadjuvant chemoradiotherapy combined with immunotherapy and biopsy or local excision. Radiotherapy uses a short-range mode, irradiating the primary tumor and high-risk areas with dose of 25 Gy. After radiotherapy, PD-L1 antibody (20mg/kg, intravenously guttae, 2courses) immunotherapy combined with 2 courses of CAPEOX chemotherapy was performed. 1-4 weeks after the end of the combined treatment plan in step 2), biopsy or local excision of the lesion is performed. |
Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.
This product is administered by intravenously guttae.
The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
Other Names:
130mg/m2, ivgtt, d1, Q3W
1000mg/m2, po, bid, d1-14, Q3W
local excision or TME surgery (total mesorectal excision) Biopsy can choose endoscopic or needle biopsy, colcal excision refers to excison of the local lession after total neoadjuvant therapy.
The total mesorectal excision can choose open, laparoscopic or robotic according to the specific condition of the patient.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Organ retention rate
Time Frame: After 2 weeks (once biopsy or local excision is done)
|
population who achieve complete clinical response after total neoadjuvant therapy
|
After 2 weeks (once biopsy or local excision is done)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TRAEs
Time Frame: Up to 3 years
|
Number of participants with treatment-related adverse events as assessed by NCI-CTCAE v5.0
|
Up to 3 years
|
Total mesorectal excision rate
Time Frame: After 2 weeks (once biopsy or local excision is done)
|
population who not achieve complete clinical response after total neoadjuvant therapy
|
After 2 weeks (once biopsy or local excision is done)
|
Total mesorectal excision rate after recurrence
Time Frame: from primary evaluation at 2 weeks after total neoadjuvant therapy finished
|
population who recurrent and have Salvage total mesorectal excision after achieving complete clinical response after total neoadjuvant therapy
|
from primary evaluation at 2 weeks after total neoadjuvant therapy finished
|
Overall survival
Time Frame: Up to 3 years
|
The proportion of participants who remain survival at 3 years
|
Up to 3 years
|
Tumor regression grade
Time Frame: After 2 weeks (once biopsy or local excision is done)
|
Tumor regression grade following short-course radiation then Envafolimab Plus CAPEOX as assessed by AJCC/CAP TRG system
|
After 2 weeks (once biopsy or local excision is done)
|
Disease free survival
Time Frame: Up to 3 years
|
The time from randomization to the first event of either recurrent disease or death
|
Up to 3 years
|
QoL
Time Frame: Up to 3 years
|
Quality of life of the patients in total neoadjuvant settings of short-course radiation followed with Adebrelimab Plus CAPEOX as assessed by Functional Assessment of Cancer Therapy - Colorectal (FACT-C) questionnaire liscenced from The Functional Assessment of Chronic Illness Therapy System ("FACIT System").
By using the Manual scoring template, some items are reverse scored.
Subscale scores, total scores and TOI scores.
The higher the score, the better the QOL.
|
Up to 3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: sheng dai, MD&PhD, China, Zhejiang Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Adenocarcinoma
- Rectal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Capecitabine
- Oxaliplatin
Other Study ID Numbers
- 20230727
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Adenocarcinoma
-
Memorial Sloan Kettering Cancer CenterRecruitingRectal Cancer | Rectal Adenocarcinoma | Adenocarcinoma of the Rectum | Locally Advanced Rectal Adenocarcinoma | HER2 Positive Rectal AdenocarcinomaUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedMucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Rectal Adenocarcinoma | Recurrent Rectal CancerUnited States
-
National Cancer Institute (NCI)CompletedMucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Adenocarcinoma of the RectumUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Rectal Carcinoma | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Rectal Mucinous Adenocarcinoma | Rectal Signet Ring Cell Adenocarcinoma | Stage IIA Rectal Cancer AJCC v7 | Stage IIB Rectal Cancer AJCC v7 | Stage IIC Rectal Cancer...United States
-
National Cancer Institute (NCI)RecruitingMetastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IV Colon Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Unresectable Colon Adenocarcinoma | Unresectable Rectal AdenocarcinomaUnited States, Puerto Rico
-
M.D. Anderson Cancer CenterActive, not recruitingMetastatic Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC... and other conditionsUnited States
-
Fox Chase Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)Active, not recruitingMucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Rectal Adenocarcinoma | Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Locally...United States
-
National Cancer Institute (NCI)CompletedRecurrent Rectal Carcinoma | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Rectal Mucinous Adenocarcinoma | Rectal Signet Ring Cell Adenocarcinoma | Stage IIA Rectal Cancer... and other conditionsUnited States
Clinical Trials on Short-course Radiation
-
Jong Hoon LeeNational Cancer Center, Korea; Samsung Medical Center; Seoul National University...UnknownRectal CancerKorea, Republic of
-
Medical University of ViennaRecruiting
-
University of RochesterTerminatedCancer, RectalUnited States
-
Tata Medical CenterCompleted
-
Trans Tasman Radiation Oncology GroupAustralasian Gastro-Intestinal Trials Group; Colorectal Surgical Society of... and other collaboratorsCompletedAdenocarcinoma of RectumAustralia, New Zealand
-
Tata Memorial HospitalTata Memorial CentreRecruiting
-
Weill Medical College of Cornell UniversityNational Cancer Institute (NCI)Recruiting
-
Polish Colorectal Cancer Study GroupPoznan University of Medical Sciences; Medical University of Lublin; Maria Sklodowska-Curie...Unknown
-
National Cancer Center, KoreaCompletedRectal CancerKorea, Republic of
-
Polish Colorectal Cancer Study GroupPoznan University of Medical Sciences; Medical University of Lublin; Maria Sklodowska-Curie... and other collaboratorsUnknown